Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Pomalidomide with Low Dose Dexamethasone Is Effective Irrespective of Primary or Secondary Resistance to Lenalidomide but the IMiD-Free Interval Is Important

Meletios A Dimopoulos, Maria Roussou, Nikolaos Kanellias, Maria Gavriatopoulou, Magdalini Migkou, Ioannis Panagiotidis, Evangelos Eleutherakis-Papaiakovou, Dimitrios Ziogas, Despina Fotiou, Stavroula Giannouli, Panagiotis Tsirigotis, MD PhD, Christos Poziopoulos, Sossana Delimpasi, Despoina Mparmparoussi, Charis Matsouka, Kostas Konstantopoulos, Evangelos Terpos, Efstathios Kastritis, MD

Blood (2016) 128 (22): 3310.

https://doi.org/10.1182/blood.V128.22.3310.3310

Published: 2016

Journal Articles

Outcomes of Newly Diagnosed Myeloma Patients Requiring Dialysis: Dialysis Independence Is Associated with Rapid Myeloma Response and Predicts for Longer Survival

Meletios A. Dimopoulos, Maria Roussou, Maria Gavriatopoulou, Despina Fotiou, Dimitrios Ziogas, Magdalini Migkou, Ioannis Panagiotidis, Evangelos Eleutherakis-Papaiakovou, Nikolaos Kanellias, Erasmia Psimenou, John N Boletis, Dimitra Bacharaki, Despoina Mparmparoussi, Charis Matsouka, Stavroula Giannouli, Evangelos Terpos, Efstathios Kastritis, MD

Blood (2016) 128 (22): 4492.

https://doi.org/10.1182/blood.V128.22.4492.4492

Published: 2016

Journal Articles

Myeloma in the Octogenarians: Disease Characteristics and Clinical Outcomes in the Era of Modern Anti-Myeloma Therapy

Meletios A. Dimopoulos, Evangelos Terpos, Maria Gavriatopoulou, Despoina Kalapanida, Evangelos Eleutherakis-Papaiakovou, Maria Roussou, Despoina Mparmparoussi, Athanasios Zomas, Dimitra Gika, Zafiris Kartasis, Charis Matsouka, Evangelos Kostis, Sofoklis Kontogiannis, Kostas Konstantopoulos, Efstathios Kastritis, MD

Blood (2014) 124 (21): 4738.

https://doi.org/10.1182/blood.V124.21.4738.4738

Published: 2014

Journal Articles

Three Drug Combinations Based on Bortezomib and Dexamethasone (VD) Backbone Improve Renal Function More Efficiently Than VD in Myeloma Patients with Severe Renal Impairment

Meletios A. Dimopoulos, Maria Roussou, Evangelos Terpos, Erasmia Psimenou, Maria Gavriatopoulou, Evangelos Eleutherakis-Papaiakovou, Despoina Kalapanida, Marios Bakogeorgos, Despoina Mparmparoussi, Theodoros P. Vassilakopoulos, Dimitra Gika, Charis Matsouka, Ioannis Boletis, Kostas Konstantopoulos, Efstathios Kastritis, MD

Blood (2014) 124 (21): 4769.

https://doi.org/10.1182/blood.V124.21.4769.4769

Published: 2014

Journal Articles

Amplification of 1q21 Is Associated with Other High Risk Cytogenetic Abnormalities and Has No Independent Prognostic Significance in Patients Treated with Novel Agents

Efstathios Kastritis, MD, Evangelos Terpos, Maria Gavriatopoulou, Maria Roussou, Evangelos Eleutherakis-Papaiakovou, Marios Bakogeorgos, Despoina Kalapanida, Spyros Orfanopoulos, Vasiliki Bampali, Thaleia Meletiou, Dimitra Gika, Despoina Mparmparoussi, Charis Matsouka, Meletios A. Dimopoulos

Blood (2014) 124 (21): 3464.

https://doi.org/10.1182/blood.V124.21.3464.3464

Published: 2014

Journal Articles

Validation Of Criteria For Renal Response In Patients With Multiple Myeloma (MM) Who Present With Severe Renal Dysfunction

Meletios A. Dimopoulos, MD, Evangelos Terpos, Maria Roussou, Evangelos Eleutherakis-Papaiakovou, Maria Gavriatopoulou, Nikolaos Kanellias, Dimitrios Christoulas, Despoina Kalapanida, Despoina Mparmparoussi, Charis Matsouka, Sofoklis Kontogiannis, Evangelos Kostis, Erasmia Psimenou, Efstathios Kastritis

Blood (2013) 122 (21): 3176.

https://doi.org/10.1182/blood.V122.21.3176.3176

Published: 2013

Journal Articles

Very Early Death (<2 months) In Myeloma Is Associated With Advanced Age, Poor Performance Status and Reduced Use Of Novel Agents, While Early Death Within 12 Months Is Associated With High Risk Features Of Both The Disease and The Patient

Efstathios Kastritis, Evangelos Terpos, Maria Roussou, Evangelos Eleutherakis-Papaiakovou, Maria Gavriatopoulou, Despoina Kalapanida, Magdalini Migkou, Nikolaos Kanellias, Dimitrios Christoulas, Dimitra Gika, Despoina Mparmparoussi, Charis Matsouka, Meletios A. Dimopoulos, MD

Blood (2013) 122 (21): 3195.

https://doi.org/10.1182/blood.V122.21.3195.3195

Published: 2013

Journal Articles

The Role of Novel Agents on Reversibility of Renal Impairment in Newly Diagnosed Patients with Multiple Myeloma; a Single Center Experience on 112 Patients,

Meletios A Dimopoulos, Maria Roussou, Maria Gkotzamanidou, Erasmia Psimenou, Despoina Mparmparoussi, Charis Matsouka, Evangelos Terpos, Efstathios Kastritis

Blood (2011) 118 (21): 3961.

https://doi.org/10.1182/blood.V118.21.3961.3961

Published: 2011

Journal Articles

Elevated Serum Lactate Dehydrogenase (LDH) Should Be Included Among the Variables Which Define High Risk Multiple myeloma

Meletios A. Dimopoulos, Efstathios Kastritis, Maria Roussou, Maria Gkotzamanidou, Magdalini Migkou, Maria Gavriatopoulou, Dimitra Gika, Charis Matsouka, Despoina Mparmparoussi, Agapi Parcharidou, Evangelos Terpos

Blood (2010) 116 (21): 2969.

https://doi.org/10.1182/blood.V116.21.2969.2969

Published: 2010

NARROW

Pomalidomide with Low Dose Dexamethasone Is Effective Irrespective of Primary or Secondary Resistance to Lenalidomide but the IMiD-Free Interval Is Important

Outcomes of Newly Diagnosed Myeloma Patients Requiring Dialysis: Dialysis Independence Is Associated with Rapid Myeloma Response and Predicts for Longer Survival

Myeloma in the Octogenarians: Disease Characteristics and Clinical Outcomes in the Era of Modern Anti-Myeloma Therapy

Three Drug Combinations Based on Bortezomib and Dexamethasone (VD) Backbone Improve Renal Function More Efficiently Than VD in Myeloma Patients with Severe Renal Impairment

Amplification of 1q21 Is Associated with Other High Risk Cytogenetic Abnormalities and Has No Independent Prognostic Significance in Patients Treated with Novel Agents

Validation Of Criteria For Renal Response In Patients With Multiple Myeloma (MM) Who Present With Severe Renal Dysfunction

Very Early Death (<2 months) In Myeloma Is Associated With Advanced Age, Poor Performance Status and Reduced Use Of Novel Agents, While Early Death Within 12 Months Is Associated With High Risk Features Of Both The Disease and The Patient

The Role of Novel Agents on Reversibility of Renal Impairment in Newly Diagnosed Patients with Multiple Myeloma; a Single Center Experience on 112 Patients,

Elevated Serum Lactate Dehydrogenase (LDH) Should Be Included Among the Variables Which Define High Risk Multiple myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only